How much revenue does Shandong Lukang Pharmaceutical make?

Shandong Lukang Pharmaceutical reported 6.23 billion CNY in revenue for fiscal year 2024, up 1.4% from 6.15 billion CNY in fiscal year 2023. In Q2 2025 revenue was 1.48 billion CNY.

Where does Shandong Lukang Pharmaceutical make most of its revenue?

China: 80% of revenue by region in fiscal year 2025, followed by Foreign (20%).

What companies are similar to Shandong Lukang Pharmaceutical?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Pacific Shuanglin Bio-pharmacy Co., Ltd. (000403.SZ), Chongqing Genrix Biopharmaceutical Co., Ltd. (688443.SS), Wanbangde Pharmaceutical Holding Group Co., Ltd. (002082.SZ), Changzhou Qianhong Biopharma Co.,ltd (002550.SZ).

Shandong Lukang Pharmaceutical Co.,Ltd. (600789.SS) Stock

About Shandong Lukang Pharmaceutical Co.,Ltd.

Shandong Lukang Pharmaceutical Co.,Ltd. operates as a pharmaceutical company in China. The company offers systemic anti-infectives, hypoglycemic agents, cardiovascular and cerebrovascular drugs, respiratory medicines, neurodegenerative disease treatments, digestive and metabolic disease drugs, antitumor drugs, and traditional Chinese and Tibetan medicines. The company also provides synthetic biolo...

At a glance

Shandong Lukang Pharmaceutical reported revenue of 6.23 billion CNY for fiscal year 2024, up 1.4% from fiscal year 2023, and net income of 394.62 million CNY. In Q2 2025 (the quarter ended June 30, 2025) revenue was 1.48 billion CNY, about flat from a year before. China was its largest region in fiscal year 2025, with 80% of revenue.

Figures from company filings; latest fiscal year ended December 31, 2024.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.